Management team takes control of biotech diagnostic screening company in buy-out from former parent Cytomyx Holdings
Cytocell Technologies has undergone a management buy-out from Cytomyx Holdings.
The acquisition includes all intellectual property covering Cytocell and its unique technology and registered designs including the future product pipeline.
"We are extremely pleased to have completed the buy-out, and to report that the management team now holds controlling shares in the firm," said Martin Lawrie, managing director.
"This significant event signals a new era for Cytocell, and we are energised by what the future holds for our team," said Brian Page, CEO.
The firm has shown consistent growth and increased revenues over the past 12 months.
Dr Lawrie projects that Cytocell will show strong growth as new products come on stream later this year.
